ImmuPharma (LON:IMM) Shares Up 9.5% - Still a Buy?

Key Points

• ImmuPharma's stock price rose by 9.5%, reaching GBX 12.10 ($0.16) amid a significant trading volume that increased by 176% compared to the average.
• The company reported a negative EPS of GBX (0.38) for the last quarter, with ongoing predictions estimating a loss of greater than -339.00 for the current year.
• ImmuPharma specializes in peptide-based therapeutics targeting autoimmune diseases, with their lead program, P140 (Lupuzor™), showing promise as a treatment for lupus and related conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was up 9.5% on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). Approximately 23,646,498 shares traded hands during mid-day trading, an increase of 176% from the average daily volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Trading Up 9.5%

The stock has a market cap of £60.47 million, a PE ratio of -1,359.55 and a beta of 1.53. The business has a fifty day simple moving average of GBX 4.46 and a two-hundred day simple moving average of GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.